Van ECK Associates Corp Buys 9,011 Shares of Edwards Lifesciences Co. (NYSE:EW)

Van ECK Associates Corp raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 126,764 shares of the medical research company’s stock after acquiring an additional 9,011 shares during the quarter. Van ECK Associates Corp’s holdings in Edwards Lifesciences were worth $8,951,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Baxter Bros Inc. boosted its position in shares of Edwards Lifesciences by 1.8% during the third quarter. Baxter Bros Inc. now owns 85,268 shares of the medical research company’s stock valued at $5,627,000 after purchasing an additional 1,510 shares in the last quarter. Invesco LLC boosted its holdings in shares of Edwards Lifesciences by 14.1% during the 3rd quarter. Invesco LLC now owns 3,469 shares of the medical research company’s stock valued at $229,000 after buying an additional 430 shares in the last quarter. Chicago Partners Investment Group LLC grew its position in shares of Edwards Lifesciences by 8.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 7,055 shares of the medical research company’s stock worth $498,000 after buying an additional 542 shares during the period. Manitou Investment Management Ltd. increased its stake in shares of Edwards Lifesciences by 59,280.6% in the 3rd quarter. Manitou Investment Management Ltd. now owns 146,670 shares of the medical research company’s stock worth $9,679,000 after acquiring an additional 146,423 shares in the last quarter. Finally, United Asset Strategies Inc. lifted its position in Edwards Lifesciences by 4.0% during the 3rd quarter. United Asset Strategies Inc. now owns 159,917 shares of the medical research company’s stock valued at $10,553,000 after acquiring an additional 6,129 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,250 shares of company stock worth $2,746,988. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 1.4 %

EW opened at $65.75 on Thursday. The firm’s 50 day simple moving average is $67.75 and its two-hundred day simple moving average is $77.18. The company has a market capitalization of $39.61 billion, a PE ratio of 9.49, a PEG ratio of 3.80 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period last year, the firm earned $0.59 EPS. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, equities analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Daiwa Capital Markets upgraded Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Oppenheimer reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Finally, Truist Financial reduced their price objective on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a research note on Friday, October 25th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.